vs
AMES NATIONAL CORP（ATLO）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是AMES NATIONAL CORP的1.0倍（$19.6M vs $18.7M），AMES NATIONAL CORP净利率更高（34.9% vs -177.4%，领先212.3%），AMES NATIONAL CORP同比增速更快（26.7% vs -11.5%），AMES NATIONAL CORP自由现金流更多（$20.7M vs $-23.1M），过去两年AMES NATIONAL CORP的营收复合增速更高（19.5% vs -12.2%）
艾姆斯国家公司是总部位于美国爱荷华州的金融控股企业，运营多家社区银行子公司，提供零售及商业银行全品类服务，涵盖存取款、个人及企业贷款、抵押贷款、财富管理等，主要服务爱荷华州中部的消费者和中小微企业。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
ATLO vs LAB — 直观对比
营收规模更大
LAB
是对方的1.0倍
$18.7M
营收增速更快
ATLO
高出38.1%
-11.5%
净利率更高
ATLO
高出212.3%
-177.4%
自由现金流更多
ATLO
多$43.8M
$-23.1M
两年增速更快
ATLO
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $19.6M |
| 净利润 | $6.5M | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | 44.3% | -168.5% |
| 净利率 | 34.9% | -177.4% |
| 营收同比 | 26.7% | -11.5% |
| 净利润同比 | 85.4% | -28.8% |
| 每股收益（稀释后） | — | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATLOLAB
| Q4 25 | $18.7M | — | ||
| Q3 25 | $16.6M | $19.6M | ||
| Q2 25 | $16.1M | $21.8M | ||
| Q1 25 | $15.5M | $40.8M | ||
| Q4 24 | $14.7M | — | ||
| Q3 24 | $13.5M | $22.1M | ||
| Q2 24 | $13.5M | $22.5M | ||
| Q1 24 | $13.1M | $45.5M |
净利润ATLOLAB
| Q4 25 | $6.5M | — | ||
| Q3 25 | $4.6M | $-34.7M | ||
| Q2 25 | $4.5M | $-33.5M | ||
| Q1 25 | $3.4M | $-26.0M | ||
| Q4 24 | $3.5M | — | ||
| Q3 24 | $2.2M | $-26.9M | ||
| Q2 24 | $2.2M | $-45.7M | ||
| Q1 24 | $2.3M | $-32.2M |
毛利率ATLOLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% |
营业利润率ATLOLAB
| Q4 25 | 44.3% | — | ||
| Q3 25 | 34.5% | -168.5% | ||
| Q2 25 | 35.0% | -118.1% | ||
| Q1 25 | 27.4% | -80.8% | ||
| Q4 24 | 29.4% | — | ||
| Q3 24 | 19.4% | -120.9% | ||
| Q2 24 | 19.0% | -134.5% | ||
| Q1 24 | 20.8% | -132.2% |
净利率ATLOLAB
| Q4 25 | 34.9% | — | ||
| Q3 25 | 27.5% | -177.4% | ||
| Q2 25 | 28.0% | -153.7% | ||
| Q1 25 | 22.3% | -63.8% | ||
| Q4 24 | 23.8% | — | ||
| Q3 24 | 16.4% | -122.0% | ||
| Q2 24 | 16.2% | -203.3% | ||
| Q1 24 | 17.6% | -70.6% |
每股收益（稀释后）ATLOLAB
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | — | $-0.09 | ||
| Q1 25 | — | $-0.07 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.07 | ||
| Q2 24 | — | $-0.12 | ||
| Q1 24 | — | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $126.8M | $129.4M |
| 总债务越低越好 | $18.4M | — |
| 股东权益账面价值 | $207.9M | $399.7M |
| 总资产 | $2.1B | $539.6M |
| 负债/权益比越低杠杆越低 | 0.09× | — |
8季度趋势，按日历期对齐
现金及短期投资ATLOLAB
| Q4 25 | $126.8M | — | ||
| Q3 25 | $108.2M | $129.4M | ||
| Q2 25 | $95.2M | $158.6M | ||
| Q1 25 | $163.4M | $150.9M | ||
| Q4 24 | $101.2M | — | ||
| Q3 24 | $59.0M | $210.6M | ||
| Q2 24 | $63.4M | $269.8M | ||
| Q1 24 | $111.4M | $287.1M |
总债务ATLOLAB
| Q4 25 | $18.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $20.0M | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益ATLOLAB
| Q4 25 | $207.9M | — | ||
| Q3 25 | $200.6M | $399.7M | ||
| Q2 25 | $193.0M | $424.5M | ||
| Q1 25 | $183.1M | $454.6M | ||
| Q4 24 | $174.7M | — | ||
| Q3 24 | $183.4M | $489.3M | ||
| Q2 24 | $167.1M | $510.3M | ||
| Q1 24 | $165.5M | $577.3M |
总资产ATLOLAB
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | $539.6M | ||
| Q2 25 | $2.1B | $557.0M | ||
| Q1 25 | $2.2B | $579.6M | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.1B | $681.5M | ||
| Q2 24 | $2.1B | $708.7M | ||
| Q1 24 | $2.2B | $777.7M |
负债/权益比ATLOLAB
| Q4 25 | 0.09× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.11× | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.3M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $20.7M | $-23.1M |
| 自由现金流率自由现金流/营收 | 110.8% | -118.1% |
| 资本支出强度资本支出/营收 | 3.4% | 4.5% |
| 现金转化率经营现金流/净利润 | 3.28× | — |
| 过去12个月自由现金流最近4个季度 | $34.2M | $-111.1M |
8季度趋势，按日历期对齐
经营现金流ATLOLAB
| Q4 25 | $21.3M | — | ||
| Q3 25 | $2.8M | $-22.2M | ||
| Q2 25 | $4.0M | $-20.7M | ||
| Q1 25 | $7.1M | $-30.3M | ||
| Q4 24 | $14.3M | — | ||
| Q3 24 | $3.1M | $-27.9M | ||
| Q2 24 | $3.9M | $-39.0M | ||
| Q1 24 | $1.4M | $-62.5M |
自由现金流ATLOLAB
| Q4 25 | $20.7M | — | ||
| Q3 25 | $2.6M | $-23.1M | ||
| Q2 25 | $3.9M | $-22.6M | ||
| Q1 25 | $6.9M | $-35.3M | ||
| Q4 24 | $14.0M | — | ||
| Q3 24 | $3.0M | $-30.1M | ||
| Q2 24 | $3.8M | $-41.0M | ||
| Q1 24 | $1.3M | $-63.3M |
自由现金流率ATLOLAB
| Q4 25 | 110.8% | — | ||
| Q3 25 | 16.0% | -118.1% | ||
| Q2 25 | 24.2% | -103.6% | ||
| Q1 25 | 44.8% | -86.6% | ||
| Q4 24 | 94.9% | — | ||
| Q3 24 | 22.5% | -136.4% | ||
| Q2 24 | 28.1% | -182.2% | ||
| Q1 24 | 10.0% | -138.9% |
资本支出强度ATLOLAB
| Q4 25 | 3.4% | — | ||
| Q3 25 | 0.6% | 4.5% | ||
| Q2 25 | 0.7% | 8.7% | ||
| Q1 25 | 1.3% | 12.4% | ||
| Q4 24 | 2.0% | — | ||
| Q3 24 | 0.5% | 10.2% | ||
| Q2 24 | 0.7% | 8.6% | ||
| Q1 24 | 0.5% | 1.7% |
现金转化率ATLOLAB
| Q4 25 | 3.28× | — | ||
| Q3 25 | 0.60× | — | ||
| Q2 25 | 0.89× | — | ||
| Q1 25 | 2.07× | — | ||
| Q4 24 | 4.07× | — | ||
| Q3 24 | 1.40× | — | ||
| Q2 24 | 1.78× | — | ||
| Q1 24 | 0.59× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATLO
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
